Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 6Blastic Plasmacytoid Dendritic Cell Neoplasm 3Myelodysplastic Syndromes 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Carboplatin 6pembrolizumab 3Paclitaxel 3Observation 3Capecitabine 3Azacitidine 3venetoclax 2pertuzumab 2olaparib 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Oxaliplatin 2Irinotecan 2Immunotherapy 2Chemoradiotherapy 2130-nm albumin-bound paclitaxel 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tegafur-gimeracil-oteracil 1taxane 1talazoparib 1tagraxofusp 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × tagraxofusp × 1 year × Clear all
NCT07007052 2025-11-26

TAGVEN

French Innovative Leukemia Organisation

Phase 2 Not yet recruiting
33 enrolled
Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡